SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: DRS/A
Document Type: DRS/A
Date Filed: 2025-10-06
Accession Number: 0001493152-25-016953
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315225016953/filename1.htm

Chunk 57 of 87
Word Count: 1214
Character Count: 7550

Document Content:

addition to the federal income tax at the participant’s usual marginal rate for ordinary income. Director Compensation Other than as set forth in the table above relating to their capacity as officers, our board members did not pay any compensation, reimburse any expense of, make any equity awards or non-equity awards to, or pay any other compensation to, any of the other non-employee members of the Board in the fiscal year ended December 31, 2024. PRINCIPAL STOCKHOLDERS The following table sets forth certain information concerning the ownership of our common stock as of the date of this prospectus, with respect to: (i) each person, or group of affiliated persons, known to us to be the beneficial owner of 5% or more of our common stock; (ii) each of our directors; (iii) each of our named executive officers; and (iv) all of our current directors and executive officers as a group.

Applicable
percentage ownership is based on 12,713,366 shares of our common stock outstanding as of the date of this prospectus, which includes
7,000,721 shares of common stock being issued upon the closing of this offering in connection with the conversion of: (i) 1,565,000
shares of our existing Series A Preferred Stock into 1,565,000 shares of common stock, (ii) $3,714,696 of our existing Series
A Secured Convertible Notes into 3,714,696 shares of our common stock, and (iii) $5,731,015 of our existing Series A-1
Secured Convertible Notes into 1,721,026 shares of our common stock as of the date of this prospectus. In addition, the number
of shares and percentage of beneficial ownership after the offering assumes the sale and gives effect to the issuance by us of shares
of common stock in this offering and assuming an initial public offering price of $ per share (the mid-point of the price range set forth
on the cover page of this prospectus). The percentage ownership information assumes no exercise of the underwriters of their’ over-allotment
option to purchase additional shares of common stock.

have determined beneficial ownership in accordance with the rules of the SEC. These rules generally attribute beneficial ownership of
securities to persons who possess sole or shared voting or investment power with respect to such securities. In addition, pursuant to
such rules, we deemed outstanding shares of common stock subject to options or warrants held by that person that are currently exercisable
or exercisable within 60 days of the date of this prospectus. We did not deem such shares outstanding, however, for the purpose of computing
the percentage ownership of any other person. Except as indicated by the footnotes below, we believe, based on the information furnished
to us, that the beneficial owners named in the table below have sole voting and investment power with respect to all shares of our common
stock that they beneficially own, subject to applicable community property laws.

Shares of common stock
Beneficially Owned Prior to
Offering Shares of common stock
Beneficially Owned After
Offering

Name and Address of Beneficial Owner (1) Number (7) (8) Percentage (2) Number Percentage (3)

Executive Officers, Directors and Director Nominees

Steve Chartier 110,530 * *

Ori Ben-Yehuda 110,000 * *

David Richmond 3,990,240	(4) 31.39	% [●]	%

Mark Ravich 988,778	(6) 7.78	% [●]	%

All directors and executive officers as a group (4 individuals) 5,199,548 39.34	% %

5% or Greater Stockholders

Michael Taglich 1,390,549	(5) 10.94	% [●]	%

Less than 1%.

(1)	Except
as otherwise indicated, the business address of our directors and executive officers is 120 Forbes Blvd., Suite 125, Mansfield, MA

(2)	Based
on 12,713,366 shares of common stock outstanding as of the date of this prospectus.

(3)	Based
on [●] shares of common stock outstanding immediately after the offering assuming no exercise of the underwriters’ over-allotment
option.

(4)	Includes
(a) 194,000 shares of common stock directly held by Mr. Richmond (including 25,665 shares of common stock from Second RSU Grant 2024
and 18,335 shares of common stock from Second RSU Grant 2025), (b) 2,415,922 shares of common stock, comprised of 148,400 Series
A shares convertible into common stock and $2,267,522 Secured Convertible Notes held by RBI BioVentrix LLC, (c) 461,223 shares of
common stock comprised of 385,832 shares of common stock and 75,391 Series A shares convertible into common stock held by RBI Opportunities
Fund LLC, (d) 355,595 shares of common stock comprised of 311,668 shares of common stock and 43,927 Series A shares convertible into
common stock held by RBI BV Private Investment, (e) 277,590 common shares comprised of 226,025 shares of common stock and 51,565
Series A shares convertible into common stock held by RBI Private Investment III LLC, (f) 255,740 shares, comprised of 215,077 shares
of common stock and 40,663 Series A shares convertible into common stock held by RBI Opportunities Fund II LLC, (g) 11,199 shares
comprised of 8,300 shares of common stock and 2,899 Series A shares convertible into common stock held by David Richmond & Stephanie
Richmond, (h) 9,486 shares comprised of 8,123 shares of common stock and 1,363 Series A shares convertible into common stock held
by RBI Private Investment I LLC, and (i) 9,485 shares, comprised of 8,123 shares of common stock and 1,362 Series A shares convertible
into common stock held by Richmond Brothers Inc. Mr. Richmond is the Manager and has voting and investment control of RBI BioVentrix
LLC, RBI Opportunities Fund LLC, RBI BioVentrix, LLC, RBI BV Private Investment, RBI Private Investment III LLC, RBI Opportunities
Fund II LLC, David Richmond & Stephanie Richmond, RBI Private Investment I LLC, and Richmond Brothers Inc, (collectively, the
“Richmond Entities”). Mr. Richmond disclaims any beneficial ownership of the securities held by the Richmond Entities,
other than to the extent of any pecuniary interest he may have therein, directly or indirectly.

(5)	Includes
(a) 381,952 shares, comprised of 119,902 shares of common stock and 262,050 Series A shares convertible into common
stock held directly by Mr. Taglich, (b) 103,654 shares of common stock held by Taglich Brothers Inc., (c) 84,408 shares
of common stock held by Michael N. Taglich & Claudia Taglich, (d) 177 shares of common stock held by Claudia Ruggiero
Taglich, (e) 3,179 shares of common stock held by Michael Taglich C/F Amanda Taglich UTMA NY, (f) 3,179 shares of common
stock held by Michael Taglich C/F Lucy Taglich UTMA NY, (g) 3,179 shares of common stock held by Michael Taglich
C/F Stella Taglich UTMA NY, (h) 130,142 shares of common stock held by Michael N. Taglich Keogh Account, (i) 3,179 shares
of common stock held by Michael Taglich TTEE Hope A Taglich Supplemental Needs Trust UAD 8/23/17, and (j) 677,500 Series A
shares convertible into common stock held by Bioventrix investors LLC. Mr. Taglich is the President of Taglich Brothers Inc.,
Michael N. Taglich Keogh Account, Michael Taglich TTEE Hope A Taglich Supplemental Needs Trust UAD 8/23/17, and Bioventrix investors
LLC and has voting and investment control over the shares held by Michael N. Taglich & Claudia Taglich, Claudia Ruggiero Taglich,
Michael Taglich C/F Amanda Taglich UTMA NY, Michael Taglich C/F Lucy Taglich UTMA NY, and Michael Taglich C/F Stella Taglich UTMA
NY (collectively, the “Taglich Entities”). Mr. Taglich disclaims any beneficial ownership of the securities held by the
Taglich Entities, other than to the extent of any pecuniary interest he may have therein, directly or indirectly.